Adcetris® (brentuximab vedotin) – New indication
March 20, 2018 - The FDA announced the approval of Seattle Genetics’ Adcetris (brentuximab vedotin) for the treatment of adult patients with previously untreated Stage III or IV classical Hodgkin lymphoma (cHL), in combination with chemotherapy.
Download PDF
